Edwards Lifesciences Co. (NYSE:EW – Get Rating) VP Daveen Chopra sold 1,000 shares of Edwards Lifesciences stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $98.31, for a total transaction of $98,310.00. Following the completion of the sale, the vice president now owns 19,911 shares in the company, valued at $1,957,450.41. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NYSE EW traded up $1.72 during trading on Thursday, reaching $98.57. The company’s stock had a trading volume of 2,988,162 shares, compared to its average volume of 2,790,473. The company has a current ratio of 3.41, a quick ratio of 2.64 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $61.29 billion, a price-to-earnings ratio of 40.40, a price-to-earnings-growth ratio of 2.85 and a beta of 1.16. Edwards Lifesciences Co. has a 12 month low of $91.52 and a 12 month high of $131.73. The firm has a 50 day moving average price of $110.08 and a 200 day moving average price of $113.19.

Edwards Lifesciences (NYSE:EW – Get Rating) last posted its quarterly earnings data on Tuesday, April 26th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The firm had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.31 billion. Edwards Lifesciences had a net margin of 28.72% and a return on equity of 25.80%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.54 EPS. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Several equities research analysts have issued reports on EW shares. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $130.00 to $122.00 and set an “outperform” rating on the stock in a research note on Thursday, January 27th. Bank of America started coverage on shares of Edwards Lifesciences in a research note on Tuesday, March 1st. They issued a “neutral” rating on the stock. Citigroup lowered their price target on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating on the stock in a research note on Tuesday, May 17th. Finally, Canaccord Genuity Group lowered their price objective on shares of Edwards Lifesciences from $152.00 to $137.00 in a research note on Wednesday, April 27th. Five analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $128.26.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Edwards Lifesciences by 7.6% during the 4th quarter. BlackRock Inc. now owns 57,040,983 shares of the medical research company’s stock worth $7,389,659,000 after acquiring an additional 4,007,132 shares during the period. Vanguard Group Inc. increased its position in Edwards Lifesciences by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 49,724,866 shares of the medical research company’s stock worth $5,853,612,000 after purchasing an additional 648,217 shares in the last quarter. State Street Corp increased its position in Edwards Lifesciences by 3.7% during the 4th quarter. State Street Corp now owns 26,920,713 shares of the medical research company’s stock worth $3,487,578,000 after purchasing an additional 948,638 shares in the last quarter. Capital International Investors increased its position in Edwards Lifesciences by 1.0% during the 1st quarter. Capital International Investors now owns 22,150,133 shares of the medical research company’s stock worth $2,607,436,000 after purchasing an additional 218,908 shares in the last quarter. Finally, Brown Advisory Inc. increased its position in Edwards Lifesciences by 18.0% during the 4th quarter. Brown Advisory Inc. now owns 16,722,298 shares of the medical research company’s stock worth $2,166,375,000 after purchasing an additional 2,548,909 shares in the last quarter. 82.54% of the stock is owned by institutional investors.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Stories

Receive News & Ratings for Edwards Lifesciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences and related companies with MarketBeat.com’s FREE daily email newsletter.